Deloitte examined 714 biotech deals (i.e. licenses and JV’s) of which 245 deals disclosed the up-front amount and/or the total “biobucks.”
• Oncology accounted for 24% of the biotech deals during 2011 and 29% of the aggregate biobucks.
• The indication category with the highest median deal size and highest median up-front payment was autoimmune/inflammatory disease with median values of $400M and $27M, respectively.
• The median up-front payment (for all indications) was $8M for discovery/preclinical stage, $10M for phase-1, $20M for phase-2, $25M for phase-3, and $59M for registration stage.
News 
Market Data 
Discover 
AI
